A selective estrogen receptor modulator (SERM). Acts as an estrogen antagonist in breast tissue and an agonist in bone and uterus. Cornerstone of breast cancer treatment for decades. Used in post-cycle therapy protocols to stimulate HPT axis recovery.
Tamoxifen is used in performance settings primarily in post-cycle therapy protocols to stimulate the recovery of natural testosterone production after HPTA suppression from anabolic use. By blocking estrogen receptors in the hypothalamus, it removes the negative feedback that estrogen exerts on GnRH pulsatility, leading to increased LH and FSH secr...
Tamoxifen is not stacked with performance compounds in the traditional sense. It is used in the PCT phase after the cycle has ended. It is commonly combined with Clomid in PCT protocols because the two SERMs work through overlapping but not identical mechanisms and the combination is believed to provide more robust LH and FSH stimulation than eithe...
The thromboembolic risk associated with Tamoxifen, documented in clinical use for breast cancer, is relevant in performance settings where individuals are often already in a prothrombotic state due to elevated hematocrit from anabolic use. The combination of elevated red blood cell mass and a compou...